Real-World Effectiveness of Vedolizumab vs Anti-TNF in Biologic-naïve Crohn's Disease Patients: A 2-year Propensity-score-adjusted Analysis from the VEDOIBD-Study.

Bernd BokemeyerSandra Plachta-DanielzikRomina di GiuseppePhilipp EfkenWolfgang MohlMartin HoffstadtThomas KrauseAxel SchweitzerElisabeth SchnoyRaja AtreyaNiels TeichLeo TrentmannRobert EhehaltPetra HartmannStefan Schreiber

Published in: Inflammatory bowel diseases (2023)

The results of this prospective, 2-year, real-world evidence study suggest that the choice of VEDO led to higher remission rates after 2 years compared with anti-TNF. This could support the role of VEDO as a first-line biologic therapy in CD.

Keyphrases

rheumatoid arthritis
end stage renal disease
randomized controlled trial
ejection fraction
chronic kidney disease
systematic review
prognostic factors
mesenchymal stem cells
systemic lupus erythematosus